ArticleEndocrine2018
The tear cytokine profile in patients with active Graves' orbitopathy.
Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2022Pooled it
- Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease.Acta ophthalmologica · 2026Article
- Research progress on the immune mechanism of thyroid-related eye disease combined with dry eye.Journal of ophthalmic inflammation and infection · 2025Article
- Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves' Disease and Graves' Ophthalmopathy.ImmunoTargets and therapy · 2025Article
- Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.Ophthalmic plastic and reconstructive surgery · 2023Review
- Tears as a Source of Biomarkers in the Diagnosis of Graves' Orbitopathy.Biomolecules · 2022Review
- The value of SPECT/CT imaging of lacrimal glands as a means of assessing the activity of Graves' orbitopathy.Endocrine connections · 2022Article
- Tear-derived exosomal biomarkers of Graves' ophthalmopathy.Frontiers in immunology · 2022Article
- Tear proteomics of orbital decompression for disfiguring exophthalmos in inactive thyroid-associated ophthalmopathy.Experimental and therapeutic medicine · 2020Article
- Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.Journal of endocrinological investigation · 2020Article
- Proteomics of Tear in Inactive Thyroid-Associated Ophthalmopathy.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe primary aim of this study is to isolate cytokines specific for active Graves' orbitopathy (GO) in the tears of affected patients. The secondary aim is to identify other cytokines of interest and to look at the profile of their levels over time.
methodsThis is a prospective pilot study conducted at the Singapore National Eye Centre. A total of 10 patients with active GO and 10 patients from each of 3 control groups were recruited. The 3 control groups were the following: age-matched normal female patients, patients with GO who were clinically inactive and patients with bilateral viral conjunctivitis. Tears from patients from the control groups were collected on a single visit. For patients with active GO, tears were collected on presentation, at 6 months, 12 months and 18 months.
resultsOf all the cytokines examined, only IL-7 yielded a difference when the concentration in patients with active GO was compared with concentrations in all the control groups. This difference was most significant at the 18-month follow-up visit.
conclusionsLow concentrations of IL-7 in tears exhibit specificity for active GO in patients nearly 2 years from the clinical onset of activity. Although using IL-7 in tears as a biomarker for disease activity may be limited due to its late manifestation, targeting immune restitution using IL-7 may have disease modifying effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.